Luboš Petruželka - Concepedia

Author

Luboš Petruželka

Also Known As

Antonio Cubillo, G Villanova, L Petruzelka, L Petruželka, L. B. Petruzelka, L. PETRUZELKA, L. Petruzelka, L. Petruz̆elka, L. Petruželka, L.B. Petruzelka

387

Publications

13.4K

Citations

H-Index

117

Concepts

All Affiliations

Charles University General University Hospital in Prague Military University Hospital Prague University of Chemistry and Technology, Prague University Hospital in Motol

About

Luboš Petruželka is an author at Charles University specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	25	44	6K
2	Health Sciences	10	10	779
3	Public Health	6	6	273
4	Engineering	2	2	91
5	Biochemistry	1	1	81

Luboš Petruželka

Publications

12.1K

Citations

H-Index

Page 1

	Year	Citations
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial Tony Mok, Yi‐Long Wu, Iveta Kudaba, The Lancet	2019	3.2K
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial Christina Davies, Hongchao Pan, Jon Godwin, The Lancet Breast OncologyLong-term EffectsMedicineRandomised TrialGynecology	2012	2K
International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study Franck Pagès, Bernhard Mlecnik, Florence Marliot, The Lancet Prognostic BiomarkersOncologyInternational ValidationMedicineImmunology	2018	2K
Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer Angelo Di Leo, Guy Jérusalem, Luboš Petruželka, Journal of Clinical Oncology	2010	630
Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study Petr Zatloukal, Luboš Petruželka, Milada Zemanová, Lung Cancer Radiation TherapyRandomized StudyMedicineBronchial NeoplasmCancer Treatment	2004	430
Perioperative Nivolumab in Resectable Lung Cancer Tina Cascone, Mark M. Awad, Jonathan Spicer, New England Journal of Medicine	2024	356
Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial Angelo Di Leo, Guy Jérusalem, Luboš Petruželka, JNCI Journal of the National Cancer Institute	2013	328
Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer – Results of the eLEcTRA trial Jens Huober, Peter A. Fasching, M. Barsoum, The Breast	2011	226
Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer Bernhard Mlecnik, Carlo Bifulco, Gabriela Bindea, Journal of Clinical Oncology	2020	222
Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial Petr Zatloukal, Luboš Petruželka, Milada Zemanová, Lung Cancer MedicinePhase IiiMetronomic TherapyPathologyBronchial Neoplasm	2003	161

Page 1